Allogeneic Hematopoietic Cell Transplant for Hairy Cell Leukemia: EBMT Experience

Overview

Journal Haematologica

Specialty Hematology

Date 2022 Dec 22

PMID 36546416

Authors

Dai Chihara

Luuk Gras

Nienke Zinger

Nicolaus Kroger

Jiri Mayer

Jakob Passweg

Regis Peffault de Latour

Jenny Byrne

William Kruger

Jan-Paul Bohn

Uwe Platzbecker

Igor Wolfgang Blau

Francesca Bonifazi

Grzegorz Helbig

Andrew McDonald

Martin Mistrik

Mohamad Mohty

Ron Ram

Jaime Sanz

Carlos Vallejo Llamas

Robert J Kreitman

Patrick J Hayden

Donal McLornan

Olivier Tournilhac

Michel van Gelder

Ibrahim Yakoub-Agha

Affiliations

Soon will be listed here.

Citing Articles

Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naïve patients with hairy cell leukemia.

Oh Y, Min G, Jeon Y, Kim T, Kim B, Park S Ann Hematol. 2025; 104(1):421-432.

PMID: 39753832 DOI: 10.1007/s00277-024-06173-1.

Hairy Cell Leukemia: Where Are We in 2023?.

Mendez-Hernandez A, Moturi K, Hanson V, Andritsos L Curr Oncol Rep. 2023; 25(8):833-840.

PMID: 37097545 PMC: 10126561. DOI: 10.1007/s11912-023-01419-z.

References

Kreitman R, Dearden C, Zinzani P, Delgado J, Karlin L, Robak T . Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018; 32(8):1768-1777. PMC: 6087717. DOI: 10.1038/s41375-018-0210-1. View

Bohn J, Neururer S, Pirklbauer M, Pircher A, Wolf D . Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population. Cancers (Basel). 2022; 14(5). PMC: 8909617. DOI: 10.3390/cancers14051242. View

Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang H, Zhou H . Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021; 5(23):4807-4816. PMC: 9153043. DOI: 10.1182/bloodadvances.2021005039. View

Chihara D, Kantarjian H, OBrien S, Jorgensen J, Pierce S, Faderl S . Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016; 174(5):760-6. PMC: 5396841. DOI: 10.1111/bjh.14129. View

Tiacci E, Park J, De Carolis L, Chung S, Broccoli A, Scott S . Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015; 373(18):1733-47. PMC: 4811324. DOI: 10.1056/NEJMoa1506583. View

Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E . Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med. 2021; 384(19):1810-1823. DOI: 10.1056/NEJMoa2031298. View

Kreitman R, Tallman M, Robak T, Coutre S, Wilson W, Stetler-Stevenson M . Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018; 131(21):2331-2334. PMC: 5969375. DOI: 10.1182/blood-2017-09-803072. View

Kreitman R, Dearden C, Zinzani P, Delgado J, Robak T, le Coutre P . Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021; 14(1):35. PMC: 7905554. DOI: 10.1186/s13045-020-01004-y. View

Kreitman R, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet A . Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2022; 141(9):996-1006. PMC: 10163281. DOI: 10.1182/blood.2021013658. View

10.

Teras L, DeSantis C, Cerhan J, Morton L, Jemal A, Flowers C . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016; 66(6):443-459. DOI: 10.3322/caac.21357. View

11.

Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang H, Zhou H . Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol. 2020; 38(14):1527-1538. PMC: 7213585. DOI: 10.1200/JCO.19.02250. View

12.

Saven A, Burian C, Koziol J, Piro L . Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998; 92(6):1918-26. View

13.

Else M, Dearden C, Matutes E, Garcia-Talavera J, Rohatiner A, Johnson S . Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009; 145(6):733-40. DOI: 10.1111/j.1365-2141.2009.07668.x. View

14.

Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D . The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001; 15(1):184-6. DOI: 10.1038/sj.leu.2401999. View

15.

Arons E, Suntum T, Stetler-Stevenson M, Kreitman R . VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009; 114(21):4687-95. PMC: 2780305. DOI: 10.1182/blood-2009-01-201731. View

16.

Zinzani P, Bonifazi F, Pellegrini C, Casadei B, Argnani L, Motta M . Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin Lymphoma Myeloma Leuk. 2012; 12(4):287-9. DOI: 10.1016/j.clml.2012.05.001. View